Tagged with IP

Greece In the price versus value discussion brought on by Greece’s economic crisis, Philips’ message is clear: they offer novel solutions that can do more for less and place the patients at the center. Philips Hellas’ Managing Director, Panagiotis Mparas, speaks about the company’s healthcare footprint in Greece; reconciling the corporate…

Switzerland Susanne Hoeppner, GM of Astellas Switzerland and board member of vips, discusses her key priorities, the culture of Swiss pharma, and the industry-wide push for faster approval times. Ms. Hoeppner, in addition to your role as general manager of Astellas, we understand you also have leadership role within the industry…

Taiwan Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s leadership in Taiwan and China and accelerate the group’s market penetration in strategic countries such as Japan and the US,…

Taiwan Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s leadership in Taiwan and China and accelerate the group’s market penetration in strategic countries such as Japan and the US,…

Ipsen These are exciting times for Ipsen in Ireland, with plans to expand the company’s already significant API manufacturing footprint to deal with increasing global demand for its products. “Sales from [Somatuline® (lanreotide) and Decapeptyl® (triptorelin)] amounted to over EUR 700 million in 2015, which was over half of Ipsen’s global…

Indonesia Parulian Simanjuntak, Executive Director at IPMG, explains the crucial role that MNCs should play within Indonesian universal healthcare coverage (JKN) and discusses the future challenges that should be addressed to enhance the national healthcare system. Indonesia is one of the strongest pharmaceutical markets within the region. Valued at USD 5.5…

Switzerland EY’s Biotech Team Leader for the EMEIA region discusses the challenges Europe’s fragmented capital markets pose for biotech startups, the under-communicated benefits of doing an IPO on the Swiss stock exchange and the implications of the Actelion acquisition for the wider Swiss life sciences ecosystem. Among other things, you are…

Mexico Sergio Olivares, managing director at Olivares, explains the TPP’s impact on the Mexican pharmaceutical industry’s dynamism and Olivares’ business proposal as a one-stop shop solution to fulfill all its current and future clients’ intellectual property needs. Olivares began as an intellectual property (IP) boutique in 1969 and is today the…

Healthcare PharmaBoardroom has spoken to a wide variety of actors at the cutting edge of healthcare digitalization over the past 12 months. Hot topics have included the healthcare industry’s slow reaction to digital trends, new modes of hospital care, homecare, and digitalization’s potential to expand access in remote and underdeveloped areas.…

Taiwan Terry Lin, general manager, and Freia Wei, director for international business at UniPharma, on the company’s move from specialty distribution to drug development and diagnostic products. With an upcoming IPO, UniPharma is considering both organic and inorganic development opportunities to further nurture its geographical expansion. Being one of the best-established…

Taiwan Jonas Wang Ph.D., Chairman and CEO of StemCyte, a global leader in Regenerative Therapy field including cell processing and transplantation located in the US, Taiwan, and India, provides us with an overview of the impressive phase II results recently received by its breakthrough regenerative therapy for spinal cord injury. While…

Philippines Ramon Aristoza, acting President and CEO of PhilHealth, discusses the current challenges the organization is facing in terms of realizing the goal of universal healthcare for the Filipino population, their strategies moving forward, as well as the successes the program has seen over the years. He also discusses the need…